Pathogen Inactivation Technologies for Cellular Blood Components: an Update
Author:
- 1 July 2014
- journal article
- review article
- Published by S. Karger AG in Transfusion Medicine and Hemotherapy
- Vol. 41 (4) , 309-325
Abstract
Nowadays patients receiving blood components are exposed to much less transfusion-transmitted infectious diseases than three decades before when among others HIV was identified as causative agent for the acquired immunodeficiency syndrome and the transmission by blood or coagulation factors became evident. Since that time the implementation of measures for risk prevention and safety precaution was socially and politically accepted. Currently emerging pathogens like arboviruses and the well-known bacterial contamination of platelet concentrates still remain major concerns of blood safety with important clinical consequences, but very rarely with fatal outcome for the blood recipient. In contrast to the well-established pathogen inactivation strategies for fresh frozen plasma using the solvent-detergent procedure or methylene blue and visible light, the bench-to-bedside translation of novel pathogen inactivation technologies for cell-containing blood components such as platelets and red blood cells are still underway. This review summarizes the pharmacological/toxicological assessment and the inactivation efficacy against viruses, bacteria, and protozoa of each of the currently available pathogen inactivation technologies and highlights the impact of the results obtained from several randomized clinical trials and hemovigilance data. Until now in some European countries pathogen inactivation technologies are in in routine use for single-donor plasma and platelets. The invention and adaption of pathogen inactivation technologies for red blood cell units and whole blood donations suggest the universal applicability of these technologies and foster a paradigm shift in the manufacturing of safe blood.Keywords
This publication has 117 references indexed in Scilit:
- Unifying the spatial epidemiology and molecular evolution of emerging epidemicsProceedings of the National Academy of Sciences, 2012
- Development of the S-303 Pathogen Inactivation Technology for Red Blood Cell ConcentratesTransfusion Medicine and Hemotherapy, 2011
- Pathogen Reduction Technology Treatment of Platelets, Plasma and Whole Blood Using Riboflavin and UV LightTransfusion Medicine and Hemotherapy, 2011
- Pathogen Inactivation of Platelet and Plasma Blood Components for Transfusion Using the INTERCEPT Blood SystemTMTransfusion Medicine and Hemotherapy, 2011
- UVC Irradiation for Pathogen Reduction of Platelet Concentrates and PlasmaTransfusion Medicine and Hemotherapy, 2011
- Main Properties of the THERAFLEX MB-Plasma System for Pathogen ReductionTransfusion Medicine and Hemotherapy, 2011
- Transfusion-Transmitted Bacterial Infections – Haemovigilance Data of German Blood Establishments (1997–2010)Transfusion Medicine and Hemotherapy, 2011
- Dose of Prophylactic Platelet Transfusions and Prevention of HemorrhageNew England Journal of Medicine, 2010
- Is dengue a threat to the blood supply?Transfusion Medicine, 2009
- A Single Mutation in Chikungunya Virus Affects Vector Specificity and Epidemic PotentialPLOS Pathogens, 2007